University of Kentucky Markey Cancer Center researchers have identified a cellular pathway that fuels the progression of aggressive, drug-resistant prostate cancer. The findings of the study, ...

Prostate cancer (PCa) is one of the most common malignant tumors in men worldwide. While early detection has improved patient outcomes, effective therapies for advanced disease remain limited.

The U.S. Food and Drug Administration (FDA) has approved the New Drug Application, or NDA, for Camcevi ETM (leuprolide mesylate 21 milligrams), a ready-to-use long-acting injectable (LAI) formulation ...

It is not unusual for a man of Biden’s age to skip prostate cancer screening, for a variety of reasons. Former president Joe Biden’s newly diagnosed prostate cancer, an aggressive form that has spread ...